Abstract
Although malaria incidence in Africa decreased substantially between 2000 and 2015 due to large-scale control efforts relying mainly on the distribution of insecticide-treated nets, this decrease has stalled in recent years. To further reduce the residual transmission, new vector control tools are needed. Transfluthrin-treated eave ribbons are considered a promising spatial repellent to protect people when they are indoors but not under an insecticide-treated net (ITN), and potentially also while they are in the peridomestic area. We conducted semi-field and field studies (published elsewhere) to assess the effectiveness of eave ribbons, the odour-baited Suna trap and the combination of these two interventions (push-pull system) on reducing mosquito-human contact and vectorial capacity in an East African setting. Here we combine the semi-field and field data to parameterise the effects of the eave ribbons repellent, the trap and the push-pull system on the mosquito population in an individual-based simulation of malaria epidemiology.
This modelling framework accounts for effects that build up over time, such as reduced infectiousness of the human population, and fully maps the uncertainty of the intervention parameter estimation on the final results. This allows us to estimate the impact of the interventions on clinical malaria in two settings: Ahero in Western Kenya and the Kilombero valley in Tanzania. Our results suggest that the transfluthrin-treated eave ribbon may substantially decrease malaria case incidence in settings with low-transmission or with low ITN coverage, especially in regions where Anopheles funestus dominates among malaria vectors and primarily uses human hosts, such as in the Kilombero setting. However, by diverting mosquitoes from indoor to outdoor host-search, the transfluthrin-treated eave ribbon may reduce the community-protective killing effect of an insecticide-treated bed net deployed at the same house. Moreover, at high but incomplete coverage, it may increase malaria risk for people that remain uncovered and are not protected by the baseline ITN intervention. Therefore, we suggest deploying this spatial repellent only as a targeted intervention complementing insufficient indoor protection by ITNs and to continue ensuring the highest possible coverage and use of ITN. The much smaller effect sizes in the Ahero setting, likely due to the lower anthropophily of An. funestus, shows that assessment of the potential of a candidate vector control tool is only meaningful under specification of an entomological and epidemiological setting. There is a high degree of uncertainty in our estimates because it is unclear whether the spatial repellent primarily kills or disarms the mosquitoes, which were shown to stop host-seeking due to the repellent in semi-field experiments. Although further research is needed to elucidate the levels of repellency, killing and disarming induced by the volatile transfluthrin under different climatic conditions, transfluthrin-treated eave ribbons offer a promising supplementary tool to ITNs to protect people at times and locations when they are in or near the house but not under the net.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This work was supported and funded by the Innovative Vector Control Consortium (IVCC), the Swiss National Science Foundation (SNF grant number 163473) and the Bill and Melinda Gates Foundation under Grant OPP1032350.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
All data produced in the present study are available upon reasonable request to the authors.
